Biospring Partners

Labviva, Inc. is a digital marketplace based in Somerville, Massachusetts, that connects researchers with suppliers of life science products, including reagents, chemicals, and instrumentation. Founded in 2015, the company offers a wide range of laboratory supplies such as antibodies, biological kits, buffers, chromatography materials, and laboratory equipment. Labviva's platform is designed to enhance procurement efficiency by providing real-time inventory tracking, AI-driven purchase automation, and insights into lab purchasing trends. This enables clients to manage their supply chains more effectively, preserve contract pricing with preferred vendors, and establish direct partnerships, all while simplifying content management for suppliers.

Labviva, Inc. is a digital marketplace based in Somerville, Massachusetts, that connects researchers with suppliers of life science products, including reagents, chemicals, and instrumentation. Founded in 2015, the company offers a wide range of laboratory supplies such as antibodies, biological kits, buffers, chromatography materials, and laboratory equipment. Labviva's platform is designed to enhance procurement efficiency by providing real-time inventory tracking, AI-driven purchase automation, and insights into lab purchasing trends. This enables clients to manage their supply chains more effectively, preserve contract pricing with preferred vendors, and establish direct partnerships, all while simplifying content management for suppliers.

Abzena is a biologics research partner that specializes in providing services and technologies for the development and manufacture of biopharmaceutical products globally, including in North America and Europe. The company focuses on biologics and antibody-drug conjugates (ADCs), offering solutions that span from early discovery to mid-phase biotherapeutic and bioconjugation drug development. Abzena's service offerings include antibody and protein engineering, developability assessment, immunogenicity assessment, and various bioassays and bioanalytics. Additionally, it provides expertise in ADC manufacturing and peptide synthesis. By serving biopharmaceutical companies and academic groups, Abzena aims to enhance the development of innovative treatments for patients. Established in 2014 and headquartered in Cambridge, United Kingdom, Abzena has positioned itself as a key player in the biopharmaceutical industry.

KINICITI is a platform established by Welsh, Carson, Anderson & Stowe that focuses on partnering with companies poised to transform the cell and gene therapy ecosystem. The organization aims to address persistent challenges in the development, manufacturing, and delivery of innovative treatments, ensuring these therapies reach patients in a cost-effective manner. By providing resources, expertise, and capital, KINICITI supports life science companies in scaling their operations and delivering significant customer value. Its investment strategy is centered on opportunities that harness technology and capabilities to drive meaningful change, ultimately facilitating the advancement and adoption of cell and gene therapies for those in need.

ixlayer is a prominent player in the health-tech sector, specializing in virtual health testing solutions for health systems, payors, biopharma, and health-focused organizations. Founded in 2018, the company provides a comprehensive platform that addresses the technical, security, regulatory, and user experience aspects of complex health testing. As the healthcare landscape increasingly embraces remote care, ixlayer enhances patient engagement and supports preventative health strategies through scalable virtual testing options. The platform can be integrated into existing patient engagement systems and portals, facilitating real-time health and wellness lab testing. ixlayer currently serves millions of patients and has successfully launched numerous testing programs for major organizations, health systems, and government entities.

Abzena is a biologics research partner that specializes in providing services and technologies for the development and manufacture of biopharmaceutical products globally, including in North America and Europe. The company focuses on biologics and antibody-drug conjugates (ADCs), offering solutions that span from early discovery to mid-phase biotherapeutic and bioconjugation drug development. Abzena's service offerings include antibody and protein engineering, developability assessment, immunogenicity assessment, and various bioassays and bioanalytics. Additionally, it provides expertise in ADC manufacturing and peptide synthesis. By serving biopharmaceutical companies and academic groups, Abzena aims to enhance the development of innovative treatments for patients. Established in 2014 and headquartered in Cambridge, United Kingdom, Abzena has positioned itself as a key player in the biopharmaceutical industry.